TMCnet News
REMINDER: Zafgen to Host ZGN-1061 Phase 2 Data Conference CallBOSTON, June 25, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected by a range of metabolic diseases, will host an investor conference call today, Monday, June 25, 2018 at 8:00 a.m., Eastern Time, to discuss the ZGN-1061 Phase 2 data results and clinical development plans as well as two nonclinical studies for ZGN-1061 that are being presented as late-breaker abstracts at the American Diabetes Association (ADA) 78th Scientific Sessions in Orlando, Florida. Investors and other interested parties may participate by dialing (844) 824-7428 in the United States or (973) 500-2177 outside the United States and referencing conference ID number 7568645. The call will also be webcast live on the company's website at https://zafgen.gcs-web.com/events-and-presentations. A press release detailing the ZGN-1061 data to be discussed on the call was issued Saturday, June 23, 2018 at 10:00 a.m. ET and can be viewed at http://zafgen.gcs-web.com/press-releases. About Zafgen Media/Investor Relations Contacts Media Investors |